Financial Incentives Double Six-Month Quit Rates to 8% in Lung Screening RCT

Researchers at Penn Medicine assigned participants to four arms: standard care, standard care plus medications, medications plus text support, or medications plus escalating cash incentives tied to biochemically confirmed abstinence. The incentive schedule paid $100 at two weeks, $200 at three months, and $300 at six months. All arms received lung screening referral. The design isolated the marginal effect of financial rewards in a population averaging decades of smoking and prior failed attempts. Absolute quit rates remained low overall, yet the doubling from 3% to 8% occurred in patients typically unresponsive to usual interventions.

The 5-percentage-point absolute gain translates to roughly 40 additional quitters per 800 participants, a clinically meaningful increment given smoking's dose-dependent mortality risk. Prior observational data and smaller trials had shown incentives improve short-term cessation, but this study demonstrates persistence to six months in an underserved screening cohort. The result aligns with behavioral economics findings that immediate, contingent rewards can overcome present bias in nicotine dependence. No arm reached double-digit success, underscoring that incentives augment rather than replace comprehensive treatment.

Next steps include implementation studies testing scalable delivery within screening programs and public acceptance of taxpayer-funded rewards. Questions remain about optimal payment size, duration beyond six months, and whether gains erode after incentives end. An RCT design with objective verification supports causal inference on the incentive effect, yet external validity depends on replication in non-screening populations and longer follow-up measuring cardiovascular and cancer outcomes.